ロード中...
A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia
BACKGROUND: Ruxolitinib is a potent and specific JAK1/JAK2 inhibitor recently approved for the treatment of myelofibrosis. PATIENTS AND METHODS: We conducted a single-center phase I/II clinical study testing 3 dose levels (50 mg BID [n=4], 100 mg BID [n=5], and 200 mg BID [n=18]). We enrolled 27 pat...
保存先:
| 出版年: | Clin Lymphoma Myeloma Leuk |
|---|---|
| 主要な著者: | , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4344906/ https://ncbi.nlm.nih.gov/pubmed/25441108 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2014.08.003 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|